<DOC>
	<DOC>NCT01250587</DOC>
	<brief_summary>The purpose of this study is to determine a safe and effective dose range for intravenous administration (infusion) of PDC31 by determining the maximum tolerated dose of PDC31 in patients with primary dysmenorrhea.</brief_summary>
	<brief_title>Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea</brief_title>
	<detailed_description>This is an open-label, multi-centre, dose-escalating first-in-human Phase I study of PDC31 in patients with primary dysmenorrhea aimed at determining the maximum tolerated dose (MTD) of PDC31 in this patient population.</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Otherwise healthy females with a history of primary dysmenorrhea Using effective birth control excluding intrauterine contraceptive device (IUCD) Must be 18 years of age or older Must give written informed consent to participate in this study Patients with an intrauterine contraceptive device or using oral contraceptives within 3 months of treatment in this study Patients with confirmed pelvic inflammatory disease, endometriosis or adenomyosis Patients who are pregnant or who test positive at baseline or are at risk of becoming pregnant while on study Patients who are breastfeeding Patients with hepatic or renal function tests greater than the upper limit of normal and deemed clinically significant by the Investigator at screening Patients with a clinically significant medical or psychiatric disorder or a serious medical conditions within the past 6 months which in the opinion of the investigator, should prohibit participation in this study Patients who have been exposure to any investigational drug within 4 weeks prior to screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Open label</keyword>
	<keyword>dose-finding Phase 1 study</keyword>
</DOC>